Polymyxin B vials

Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid...

Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid...

Colistimethate sodium is a prodrug of colistin which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Indication: Used in the treatment of patients with serious i...

Colistimethate sodium is a prodrug of colistin, which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and especially Pseudomonas aeruginosa.

Indication:&nbs...

Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.

Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus au...

Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.

Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus aureus...

Amphotericin B is a mixture of polyenes active against a wide variety of fungi e.g. Aspergillus, Candida and Cryptococcus species.

Indication: Used in the treatment of severe, invasive, potentially life-threatening fungal infections (mycosis) typically in immunocompromised...

Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.

Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants...

Bacitracin zinc is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci. The zinc complex adds stability to the component, making bacitracin zinc more stable compared to bacitracin.

Indication: Used i...

Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

...

Daptomycin is a lipopeptide antibiotic active against gram-positive bacteria such as Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isol...

Gramicidin is a mixture of linear polypeptides active against a variety of gram-positive bacteria.

Indication: Ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacter...

Copenhagen, Denmark, 2 October 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, today welcomes Michael Kocher as its new Chief Executive Officer. With more than a decade of experience in commercial leadership roles at Novartis and Sandoz, Michael Kocher has significant expertise in the complexities of the global pharmaceutical landscape. His tenure at Sandoz, where he served as Global Head of Commercial Operations and subsequently as Global Head of B2B, underscored his pivotal role in transforming the company into a leading global partner within the industry. A native of Germany and a trained chemist, Michael Kocher's expertise and vision align with Xellia Pharmaceuticals' commitment to delivering anti-infective treatments and critical care therapies.

Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers.

Copenhagen, Denmark, 14 June 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leading pharmaceutical company, announces the appointment of Michael Kocher as its new Chief Executive Officer.

Michael Kocher, Head of Global B2B-Business in Sandoz and Country President of Novartis in Austria is appointed as CEO of Xellia starting 1 October 2023 where he will replace Carl-Åke Carlsson, who has been with Xellia as CEO since 2008.

Xellia Manufacturing Collage 2023

Copenhagen, Denmark and Buffalo Grove, IL, USA - 16 December 2022 Xellia Pharmaceuticals announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care. 

Sustainability and AMR advocacy

Copenhagen, Denmark, 18 April 2023 - Xellia Pharmaceuticals (‘Xellia’ or the ‘Group’), a specialty pharmaceutical company focusing on providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions, reports its business update for the year ending December 31, 2022 and outlook for 2023.

Copenhagen, Denmark, 21 January 2021 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, today announces that it has become a member of Medicines for Europe, effective January 1st 2021.